Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides

Open access
Wang, Dali, Wang, Qiwei, Wang, Yuyan, Chen, Peiru, Lu, Xueguang, Jia, Fei, Sun, Yehui, Sun, Tingyu, Zhang, Lei, Che, Fangyuan, He, Jialu, Lian, Liming, Morano, Gemma, Shen, Michael, Ren, Mengqi, Dong, Sijia S., Zhao, Jean J., Zhang, Ke · 2022 · Proceedings of the National Academy of Sciences

Abstract

The mutant form of the guanosine triphosphatase (GTPase) KRAS is a key driver in human tumors but remains a challenging therapeutic target, making KRAS MUT cancers a highly unmet clinical need. Here, we report a class of bottlebrush polyethylene glycol (PEG)–conjugated antisense oligonucleotides (ASOs) for potent in vivo KRAS depletion. Owing to their highly branched architecture, these molecular nanoconstructs suppress nearly all side effects associated with DNA–protein interactions and substantially enhance the pharmacological properties of the ASO, such as plasma pharmacokinetics and tumor uptake. Systemic delivery to mice bearing human non–small-cell lung carcinoma xenografts results in a significant reduction in both KRAS levels and tumor growth, and the antitumor performance well exceeds that of current popular ASO paradigms, such as chemically modified oligonucleotides and PEGylation using linear or slightly branched PEG. Importantly, these conjugates relax the requirement on the ASO chemistry, allowing unmodified, natural phosphodiester ASOs to achieve efficacy comparable to that of chemically modified ones. Both the bottlebrush polymer and its ASO conjugates appear to be safe and well tolerated in mice. Together, these data indicate that the molecular brush–ASO conjugate is a promising therapeutic platform for the treatment of KRAS -driven human cancers and warrant further preclinical and clinical development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.2113180119

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. Chemical and simulated structures of pacDNAs. (A) Antisense-targeted region of the KRAS mRNA. Highlighted deoxyguanosine (red) in the KRAS ASO sequence is used for midsequence conjugation to the bottlebrush polymer. (B) Polymer, ASO, and linker chemistry. (C) Sample ID and chemical structure. Clv: cleavable; m: midsequence conjugation; PO: phosphodiester; PS: phosphorothioate; YPEG: Polymer 2. (D) A structural model from a coarse-grained molecular dynamics simulation of the pacDNA. A crystal structure of recombinant human DNase I is placed next to the pacDNA for size comparison.
Fig. 1. Chemical and simulated structures of pacDNAs. (A) Antisense-targeted region of the KRAS mRNA. Highlighted deoxyguanosine (red) in the KRAS ASO sequence is used for midsequence conjugation to the bottlebrush polymer. (B) Polymer, ASO, and linker chemistry. (C) Sample ID and chemical structure. Clv: cleavable; m: midsequence conjugation; PO: phosphodiester; PS: phosphorothioate; YPEG: Polymer 2. (D) A structural model from a coarse-grained molecular dynamics simulation of the pacDNA. A crystal structure of recombinant human DNase I is placed next to the pacDNA for size comparison.CC BY-NC-ND · PubMed Central
Fig. 2. Cellular uptake and phenotypic response in vitro. (A) Flow cytometry measurement of NCI-H358 cells treated with Cy3-labeled free ASOs (both PO and PS backbones) and corresponding pacDNAs (250 to 5,000 nM; ASO-basis) for 4 h. (B) Cellular uptake in NCI-H358 cells as indicated by mean cellular fluorescence, showing a “leveling” effect where the bottlebrush polymer reduces the uptake of normally high-uptake ASO but boosts that of low-uptake ASO. a.u., arbitrary units. (C) Confocal microscopy of NCI-H358 cells treated with fluorescently labeled PO or PS forms of molecular ASO and pacDNA. (D) Dose-dependent depletion of KRAS in NCI-H358 cells by pacDNAs. (E) Western blot analysis of MAPK signaling in NCI-H358 cells after treatment with pacDNAs for 72 h. (F) Inhibitive effect in the proliferation of KRAS mutant cells (NCI-H358) vs. wild-type cells (PC9) by KRAS depletion using free ASOs and pacDNAs. Statistical analysis was performed using two-way ANOVA with Sidak’s multiple comparison testing (****P < 0.0001).
Fig. 2. Cellular uptake and phenotypic response in vitro. (A) Flow cytometry measurement of NCI-H358 cells treated with Cy3-labeled free ASOs (both PO and PS backbones) and corresponding pacDNAs (250 to 5,000 nM; ASO-basis) for 4 h. (B) Cellular uptake in NCI-H358 cells as indicated by mean cellular fluorescence, showing a “leveling” effect where the bottlebrush polymer reduces the uptake of normally high-uptake ASO but boosts that of low-uptake ASO. a.u., arbitrary units. (C) Confocal microscopy of NCI-H358 cells treated with fluorescently labeled PO or PS forms of molecular ASO and pacDNA. (D) Dose-dependent depletion of KRAS in NCI-H358 cells by pacDNAs. (E) Western blot analysis of MAPK signaling in NCI-H358 cells after treatment with pacDNAs for 72 h. (F) Inhibitive effect in the proliferation of KRAS mutant cells (NCI-H358) vs. wild-type cells (PC9) by KRAS depletion using free ASOs and pacDNAs. Statistical analysis was performed using two-way ANOVA with Sidak’s multiple comparison testing (****P < 0.0001).CC BY-NC-ND · PubMed Central
Fig. 3. Plasma PK and biodistribution in mice. (A) Plasma PK of pacDNAs, free ASO (both in PO and PS forms), and the bottlebrush polymer in C57BL/6 mice. (B) Fluorescence monitoring of i.v. injected Cy5-labeled pacDNAs and controls in BALB/c-nu mice bearing NCI-H358 xenograft. (C) Ex vivo imaging of tumors and other major organs 14 or 91 d postinjection. Imaging settings were kept identical. (D) Confocal microscopy of cryosectioned tumor tissue 24 h postinjection, showing tumor penetration (PS pacDNA). Statistical analysis was performed using two-way ANOVA with Tukey’s multiple comparison testing. ****P < 0.0001.
Fig. 3. Plasma PK and biodistribution in mice. (A) Plasma PK of pacDNAs, free ASO (both in PO and PS forms), and the bottlebrush polymer in C57BL/6 mice. (B) Fluorescence monitoring of i.v. injected Cy5-labeled pacDNAs and controls in BALB/c-nu mice bearing NCI-H358 xenograft. (C) Ex vivo imaging of tumors and other major organs 14 or 91 d postinjection. Imaging settings were kept identical. (D) Confocal microscopy of cryosectioned tumor tissue 24 h postinjection, showing tumor penetration (PS pacDNA). Statistical analysis was performed using two-way ANOVA with Tukey’s multiple comparison testing. ****P < 0.0001.CC BY-NC-ND · PubMed Central
Fig. 4. Antitumor efficacy in KRASMUT NSCLC xenograft models. (A) NCI-H358 tumor volume changes in 36 d with i.v. administration of PBS, ASOs, and pacDNAs at equivalent ASO doses (0.5 μmol/kg) every third day (treatment started on day 0). (B) Kaplan–Meier endpoint animal survival analysis for the NCI-H358 xenograft study. Data are shown as the percentage of remaining animals with tumors less than four times the initial starting volume in each treatment group. (C) Tumor growth inhibition of NCI-H358 xenografts at a reduced ASO dosage (0.1 μmol/kg). (D) Immunohistostaining of tumor cryosections, showing reduced KRAS expression in pacDNA-treated groups. (E) H&E staining of tumor tissues after the treatment period. (F) NCI-H1944 tumor volume changes with i.v. administration of PBS, PO pacDNA, and PS pacDNA at equivalent ASO doses (2.0 μmol/kg) every third day (treatment started on day 0). (G) Kaplan–Meier survival curves for NCI-H1944 tumor-bearing mice. Data are shown as the percentage of remaining animals with tumors less than four times the initial starting volume in each treatment group. (H) Body weight changes of NCI-H1944 tumor-bearing mice during the treatment period. For tumor inhibition, statistical analysis was performed using two-way ANOVA with Tukey’s multiple comparison testing. For animal survival analysis, statistical significance was calculated by the log-rank test. ****P < 0.0001, **P < 0.01. NS, not statistically significant.
Fig. 4. Antitumor efficacy in KRASMUT NSCLC xenograft models. (A) NCI-H358 tumor volume changes in 36 d with i.v. administration of PBS, ASOs, and pacDNAs at equivalent ASO doses (0.5 μmol/kg) every third day (treatment started on day 0). (B) Kaplan–Meier endpoint animal survival analysis for the NCI-H358 xenograft study. Data are shown as the percentage of remaining animals with tumors less than four times the initial starting volume in each treatment group. (C) Tumor growth inhibition of NCI-H358 xenografts at a reduced ASO dosage (0.1 μmol/kg). (D) Immunohistostaining of tumor cryosections, showing reduced KRAS expression in pacDNA-treated groups. (E) H&E staining of tumor tissues after the treatment period. (F) NCI-H1944 tumor volume changes with i.v. administration of PBS, PO pacDNA, and PS pacDNA at equivalent ASO doses (2.0 μmol/kg) every third day (treatment started on day 0). (G) Kaplan–Meier survival curves for NCI-H1944 tumor-bearing mice. Data are shown as the percentage of remaining animals with tumors less than four times the initial starting volume in each treatment group. (H) Body weight changes of NCI-H1944 tumor-bearing mice during the treatment period. For tumor inhibition, statistical analysis was performed using two-way ANOVA with Tukey’s multiple comparison testing. For animal survival analysis, statistical significance was calculated by the log-rank test. ****P < 0.0001, **P < 0.01. NS, not statistically significant.CC BY-NC-ND · PubMed Central
Fig. 5. Unwanted hemolytic and immunological activities of pacDNAs. (A) Hemolysis of human blood (type O+) treated with pacDNA and controls, as determined by spectrophotometric measurement of hemoglobin present in the supernatant of centrifuged RBC suspensions. The %RBC hemolysis is defined as the percentage of hemoglobin present in the supernatant compared with the total hemoglobin released by Triton X-100 treatment. (Inset) Photograph of centrifuged RBC suspensions. Sample identity for pacDNAs: 4. PO pacDNA, 5. PS pacDNA, 6. PS pacDNAClv, 7. PS pacDNAm, 8. PS pacDNAm,Clv. (B) Selected cytokine levels in the serum in C57BL/6 mice following injection of pacDNAs or controls. (C) Anti-PEG IgM levels and (D) anti-PEG IgG levels in the serum of C57BL/6 mice after repeated injections of pacDNAs and controls at timed intervals. (E) Repeated plasma PK measurements after four sequential i.v. administration of pacDNAs or free bottlebrush polymer in C57BL/6 mice. Plasma ASO or polymer levels were monitored after each injection. Statistical analysis was performed using one-way ANOVA with Tukey’s multiple comparison testing. ****P < 0.0001, *P < 0.05. NS, not statistically significant.
Fig. 5. Unwanted hemolytic and immunological activities of pacDNAs. (A) Hemolysis of human blood (type O+) treated with pacDNA and controls, as determined by spectrophotometric measurement of hemoglobin present in the supernatant of centrifuged RBC suspensions. The %RBC hemolysis is defined as the percentage of hemoglobin present in the supernatant compared with the total hemoglobin released by Triton X-100 treatment. (Inset) Photograph of centrifuged RBC suspensions. Sample identity for pacDNAs: 4. PO pacDNA, 5. PS pacDNA, 6. PS pacDNAClv, 7. PS pacDNAm, 8. PS pacDNAm,Clv. (B) Selected cytokine levels in the serum in C57BL/6 mice following injection of pacDNAs or controls. (C) Anti-PEG IgM levels and (D) anti-PEG IgG levels in the serum of C57BL/6 mice after repeated injections of pacDNAs and controls at timed intervals. (E) Repeated plasma PK measurements after four sequential i.v. administration of pacDNAs or free bottlebrush polymer in C57BL/6 mice. Plasma ASO or polymer levels were monitored after each injection. Statistical analysis was performed using one-way ANOVA with Tukey’s multiple comparison testing. ****P < 0.0001, *P < 0.05. NS, not statistically significant.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 57 references

Cited by

See all 49

Metadata

Authors
Wang, D., Wang, Q., Wang, Y., Chen, P., Lu, X., Jia, F., Sun, Y., Sun, T., Zhang, L., Che, F., He, J., Lian, L., Morano, G., Shen, M., Ren, M., Dong, S. S., Zhao, J. J., & Zhang, K.
Affiliations
  • Northeastern University (US)
  • Harvard University (US)
  • Koch Institute for Integrative Cancer Research At MIT (US)
Corresponding author
  • Zhao, Jean J.
  • Zhang, Ke
Venue
Proceedings of the National Academy of Sciences
Published
2022-07-14
Volume
119
Issue
29
Pages
e2113180119-e2113180119
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W4285387133
Cited by
43
References
57
Citations by year
2026: 10 · 2025: 10 · 2024: 12 · 2023: 5 · 2022: 6
FWCI
2.69
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • HHS | NIH | National Cancer Institute (1R01CA251730)
  • HHS | NIH | National Institute of General Medical Sciences (1R01GM121612)
  • National Science Foundation (2004947)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
Keywords
KRAS mutation, antisense oligonucleotides, bottlebrush polymers, molecular brushes, non-small cell lung cancer, pharmacokinetics, tumor uptake, antitumor efficacy, drug delivery
MeSH terms
Animals, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Polyethylene Glycols, Proto-Oncogene Proteins p21(ras), Oligonucleotides, Antisense, Xenograft Model Antitumor Assays, Mice, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides. https://app.cochat.ai/papers/10.1073/pnas.2113180119
The paper
Wang, D., Wang, Q., Wang, Y., Chen, P., Lu, X., Jia, F., Sun, Y., Sun, T., Zhang, L., Che, F., He, J., Lian, L., Morano, G., Shen, M., Ren, M., Dong, S. S., Zhao, J. J., & Zhang, K. (2022). Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2113180119

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.